The Commonwealth Bank of Australia (ASX: CBA) share price has dropped slightly at the time of writing to $66.02. However, it has fallen 26.16% since its February high of $91.05. 

Why is the CBA share price down since February?

The coronavirus pandemic is the obvious factor affecting the CBA share price. But some investors may be wondering why it’s still lower when Australia seems to be recovering from the effects of COVID-19.

The share price is down because the economic impact of coronavirus is still taking hold. According to some, it could get worse as fiscal stimulus packages, such as the government’s Jobkeeper program, are no longer in place. Commonwealth Bank CEO Matt Comyn believes that the economy faces its biggest test next year when fiscal stimulus is wound back. He also predicts a long and uneven recovery.

This means that the hard times for CBA may be just beginning and with 10% of its loans currently deferred, the bank has a significant amount of borrowers that may struggle to repay their loans as normal.

In addition, CBA has predicted that house prices could fall as much as 10% nationwide, although it recently revised these forecasts down to 6%. If this took place, there may be borrowers who cannot repay their loans and in the case of default cannot sell their property at a price that will allow them to repay their loan. This could lead to a build-up of significant bad debt. 

While the bank has made credit provisions of $6.4 billion to absorb bad debts on its balance sheet, some have criticised this as inadequate. They have suggested that the bank may be in for a more negative scenario than it has predicted.

Despite all the doom and gloom, CBA’s cash net profit was down by only 11.3% in the year to 30 June 2020 against the prior year, while its share price is down significantly more from February highs.

About the CBA share price 

The Commonwealth Bank is Australia’s largest bank and offers a wide range of banking services. It has businesses in Australia and abroad. CBA has been listed on the ASX since 1991.

The CBA share price is up 25.8% from its 52-week low of $53.44, however, it is down 15.84% since the beginning of the year. The CBA share price is down 15.85% since this time last year.

More reading

• ASX 200 drops over 2%, tech and oil fall
• ASX banks facing new battle with zombie army
• Big 4 ASX banks lower in share market selloff
• Here’s why some ASX dividend shares just go nowhere
• Half of ASX 200 stocks at risk as China-Australia relations hit new low

Motley Fool contributor Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the CBA (ASX:CBA) share price has fallen 26% since February appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2FhNpXk

The Sigma Healthcare Ltd (ASX: SIG) share price is rising today as the company released its half year results. At the time of writing, the Sigma share price is up 3.91% to 66.5 cents.

Sigma is a full line wholesale and distribution business to pharmacy. It is the owner of well-known Australian pharmacy retail brands Amcal Max and Discount Drug stores.

How is Sigma performing so far this year?

Financially speaking, Sigma has been resilient through the challenging 1H21 environment. The company reported half year sales revenue of $1.64 billion which was down 12.5% on the prior half year. However, thanks to prudent cost saving measures, the company’s net profit after tax (NPAT) fell by significantly less. Sigma’s NPAT was down only 5.1% to $4.7 million, despite the effects of COVID-19. This result was aided by expansion as Sigma’s businesses continue to grow as a proportion of total earnings, with some one-off benefits in 1H21. This assisted in absorbing the negative impact of the pandemic.

It must be noted that the impact of the sale of two of Sigma’s distribution centres at a profit for $172 million is not considered in this report and will be reflected in the 2H21 report.

In positive news for the company, volumes in July 2020 were above the same month last year with the trend showing no signs of slowing down. Additionally, Sigma has seen its net promoter score increase significantly since the restructure in early January. Fundamentally, this means that customers are becoming more loyal to Sigma’s brands. This metric can also be a good predictor of business growth so is a positive sign for the Sigma share price.

Outlook for the Sigma share price

Since Sigma has restructured its business, the drug company has been on a solid road to recovery. There is evidence of this in the company’s half year report. Net debt is expected to significantly reduce by $100 million to ~$75 million by 31 January, 2021. However, given the influence of the pandemic, no formal guidance is being provided for FY21, with dividends also being reviewed.

The stock has come a long way in turning around investor sentiment and COVID-19 may be helping. In the volatile environment created by the pandemic, Sigma’s relatively stable income stream could be seen as more highly prized than ever before.

The Sigma share price is currently trading nearly 17% higher since the start of the year. Outpacing the return of the All Ordinaries Index (ASX: XAO), currently sitting at -10%, by a huge 27%.

More reading

• Top brokers name 3 ASX shares to sell today

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Sigma (ASX:SIG) share price rises on half year results appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/33cM5NL

At lunch on Thursday the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. The benchmark index is currently up 0.7% to 5,919 points.

Here’s what is happening on the ASX 200 today:

Nearmap capital raising.

The Nearmap Ltd (ASX: NEA) share price is in a trading halt on Thursday whilst it undertakes a $90 million capital raising. This comprises a $70 million institutional placement at an underwritten floor price of $2.69 and a $20 million share purchase plan. Management advised that it is raising the funds to capitalise on the momentum of the business and the tailwinds in the industry. This includes scaling its investment in sales and marketing, particularly in North America.

Tech shares rebounding.

The likes of Afterpay Ltd (ASX: APT) and Appen Ltd (ASX: APX) are rebounding on Thursday after investors returned to the tech sector. This follows a positive night of trade on the technology-focused Nasdaq index. Overnight the famous index jumped a sizeable 2.7% higher. At the time of writing the S&P ASX All Technology index is up by a solid 2.3%.

Big four banks drop lower.

The big four banks have failed to follow the market higher and are acting as a drag on the ASX 200. All four banks are trading lower at lunch, with the National Australia Bank Ltd (ASX: NAB) share price the worst performer. Its shares are currently down a disappointing 0.7%.

Best and worst ASX 200 performers.

The best performer on the ASX 200 on Thursday has been the Clinuvel Pharmaceuticals Limited (ASX: CUV) share price with a 7% gain. This morning it announced that it is looking to expand its SCENSSE product to treat the disease xeroderma pigmentosum. The worst performer has been the Resolute Mining Limited (ASX: RSG) share price with a 7% decline. This morning it revealed that workers at its Syama operation in Mali have threatened to strike.

More reading

• Why you shouldn’t be concerned by the high PE multiples of ASX tech shares
• Why Afterpay, Clinuvel, IDP Education, & Saracen shares are charging higher
• Why the Resolute Mining (ASX:RSG) share price is crashing 13% lower
• Why the CLINUVEL (ASX:CUV) share price is shooting higher
• Nearmap (ASX:NEA) share price halted for $90 million capital raising

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nearmap Ltd. The Motley Fool Australia owns shares of AFTERPAY T FPO and Appen Ltd. The Motley Fool Australia has recommended Nearmap Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post ASX 200 up 0.7%: Nearmap (ASX:NEA) launches capital raising, Afterpay (ASX:APT) rebounds appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2Zq4sxH

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is bouncing back from yesterday’s heavy decline. At the time of writing the benchmark index is up 0.75% to 5,922.8 points.

Four shares that are climbing more than most today are listed below. Here’s why they are charging higher:

The Afterpay Ltd (ASX: APT) share price is up 4% to $77.14. Investors have been buying the payments company’s shares following a rebound on the technology-focused Nasdaq index overnight. It isn’t just Afterpay that is on the rise today. At the time of writing the S&P ASX All Technology index is up by a solid 2.2%.

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has jumped 7% to $21.08. This morning the biopharmaceutical company announced that it is looking to expand its SCENSSE product to treat the disease xeroderma pigmentosum. This is a rare genetic disorder where sufferers have the most extreme deficiencies in their DNA repair processes, leading to a 10,000-fold increase in their risk of skin cancer. There is no known cure for XP at present. SCENSSE is currently used to treat rare genetic disorder Erythropoietic Protoporphyria.

The IDP Education Ltd (ASX: IEL) share price is up 3% to $19.42. This gain appears to have been driven by a broker note out of Goldman Sachs this morning. According to the note, the broker has retained its buy rating and lifted its price target by almost a third to $22.50. It believes the student placement and language testing company is well positioned for the eventual restart of the international student market.

The Saracen Mineral Holdings Limited (ASX: SAR) share price is 3% higher at $5.16. Investors have been buying Saracen’s shares after a rise in the gold price overnight. This was driven by weakness in the U.S. dollar and concerns over the AstraZeneca-Oxford University coronavirus vaccine candidate. It isn’t just Saracen pushing higher today. At the time of writing the S&P/ASX All Ordinaries Gold index is up 2.2%.

More reading

• Why the CLINUVEL (ASX:CUV) share price is shooting higher
• Where to invest your first $1,000 into ASX shares
• 5 things to watch on the ASX 200 on Thursday
• ASX 200 drops over 2%, tech and oil fall
• Why the Laybuy (ASX:LBY) share price is tanking today

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Idp Education Pty Ltd. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Afterpay, Clinuvel, IDP Education, & Saracen shares are charging higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3m7xTyk

The market may be charging higher on Thursday but the same cannot be said for the Resolute Mining Limited (ASX: RSG) share price.

In morning trade the gold miner’s shares crashed 13% lower to 92 cents.

This latest decline means the Resolute share price is now down 45% from its 52-week high.

Why is the Resolute share price crashing lower?

Investors have been selling the company’s shares in recent weeks due to developments in Mali where its key Syama operation is based.

Last month Resolute’s shares came under pressure following the resignation of Mali’s President after he was detained by mutinying soldiers. Given that the company’s Syama gold operation contributed 59.4% of its total production during the June quarter, any disruption could have a major impact on its results.

This morning the company revealed that its Syama operation is about to be disrupted, but not because of the change of government.

According to the release, it has received a strike notice from the local workers union informing of plans to observe a 10-day strike order if certain demands are not met. The principal demand of the union relates to a request to reinstate Syama workers who have been stood down on full pay due to the company’s COVID-19 protocols.

Resolute has implemented a comprehensive, company-wide response to the coronavirus pandemic. At Syama, a decision was made to limit the travel of non-essential workers from outside the surrounding region to the mine site. This decision was made to limit the risk of transmission of the virus between separate regional populations and to maintain Syama’s isolation from the virus.

Resolute advised that it has informed the union that the strike notice is irresponsible, opportunistic, and represents a breach of the commitments made in the Syama Workforce Stability Agreement. It is currently considering how to respond to the strike notice.

In light of the uncertainty this is causing, Resolute has withdrawn its production and cost guidance for FY 2020.

More reading

• 5 things to watch on the ASX 200 on Thursday
• 5 things to watch on the ASX 200 on Wednesday
• These were the worst performing ASX 200 shares in August
• 5 things to watch on the ASX 200 on Tuesday
• Resolute Mining share price on watch after half-year result

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Resolute Mining (ASX:RSG) share price is crashing 13% lower appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3ihf5dB

The CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price has been a very strong performer on Thursday.

In morning trade the biopharmaceutical company’s shares are up 5.5% to $20.80.

Why is the CLINUVEL share price storming higher?

Investors have been buying CLINUVEL’s shares after it announced plans to expand its SCENESSE drug (afamelanotide 16mg) to treat the disease xeroderma pigmentosum (XP).

XP is rare genetic disorder affecting 1 in 1 million in the United States and Europe. Sufferers have the most extreme deficiencies in their DNA repair processes, leading to a 10,000-fold increase in their risk of skin cancer. There is no known cure for XP at present.

Having commercialised SCENESSE in Europe and the USA for the rare genetic disorder Erythropoietic Protoporphyria (EPP), CLINUVEL is now aiming to confirm how intervention with the drug enhances elimination of photoproducts and regeneration of DNA.

CLINUVEL’s Chief Scientific Officer, Dr Dennis Wright, commented “In SCENESSE we have a hormone acting on various organs and receptors, but most of all known to protect human DNA. Our task is to confirm how DNA regeneration occurs within genetically affected patients and healthy subjects.”

“Tragically, XP provides an extreme model of what happens to our skin if UV-induced damage is left unrepaired. From a young age, XP patients are incapable of responding to DNA damage caused by UV exposure and experience disfiguring and aggressive skin cancers.”

“After two decades of clinical research, I’m delighted that our team can now focus on the XP patients who are severely affected by UV radiation leaving them a short life expectancy. We will facilitate treatment for the first patient in the next few weeks,” Dr Wright said.

The company advised that the first clinical results from the DNA repair program are expected to be reported in 2021.

More reading

• Why Afterpay, Clinuvel, IDP Education, & Saracen shares are charging higher
• These are the 10 most shorted ASX shares
• These are the 10 most shorted ASX shares
• Clinuvel share price sinks lower following disappointing FY 2020 result
• These are the 10 most shorted shares on the ASX

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the CLINUVEL (ASX:CUV) share price is shooting higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3iewqni

The Sky Network Television Ltd (ASX: SKT) share price has sank in early morning trade following the release of the company’s FY20 results to the market. At the time of writing, the Sky share price has retreated 9.38% to 14.5 cents. Let’s take a look at what Sky achieved for the last financial year.

FY20 results

For the 12 months that ended on 30 June, Sky reported a mixed result although its performance was in line with the upper-end of its guidance range. Revenue declined 6% to NZ$747.6 million but with notable increases in its revenue streaming segment, jumping 35%

Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) fell 28% to NZ$164.2 million.

On the company’s bottom line, Sky reported a loss after tax of NZ$156.8 million that included a non-cash impairment of goodwill of NZ$177.5 million. Operating profit before the impairment stood at NZ$44.9 million.

Net cash from operating and investing activities came in at NZ$82.7 million. Sky advised that the solid financial position will allow it to navigate through any further COVID-19 uncertainty and deliver on strategy in FY21.

The board determined that no final dividend will be paid as the company intends to reinvest available cash flow during FY21.

COVID-19 response

Sky noted that strong engagement and viewership levels were recorded in its satellite and streaming services during the lockdown period. Access to news, shows, documentaries, movie and e-sports content kept customers informed and entertained.

In addition, the company took proactive steps to minimise its customer ‘spin down’ from sport packages that proved to be effective. The complimentary upgrades were well received, with only 8% of sport satellite customers downgrading their packages.

The return of premium live sport in May 2020 saw the previously downgraded packages renew their subscriptions in the final five weeks of FY20. As a result, Sky’s sport segment saw double digit growth in May and June.

Commercial customers were heavily impacted by COVID-19 restrictions. However, the relaxing of domestic travel restrictions and faster than anticipated return of sport saw a return of normal billing for licenced customers from July.

Outlook

Moving into FY21, Sky provided a guidance of revenue in the range of NZ$660 – NZ$700 million. Furthermore, it anticipates EBITDA will be between NZ$125 – NZ$140 million and a net profit after tax of NZ$10 – NZ$20 million.

Sky announced its intention to enter the broadband market as it sees more customers watching content over broadband. The company is currently trailing its broadband service and is expected to expand to a group of customers before Christmas, followed by a full launch in 2021.

About the Sky share price

The Sky share price has been on a downhill trend for the last 6 years losing up to 98% of its value. Looking at the last 12 months, the Sky share price is up 26% from its 52-week low of 11.5 cents, but is down 74% from this time last year.

More reading

• Stock market crash part 2: how I’d capitalise on buying opportunities to make a million
• Nearmap (ASX:NEA) share price halted for $90 million capital raising
• Whispir (ASX:WSP) share price sinks 9.5% lower on major shareholder sell-down
• Warren Buffett is investing in this hot tech IPO. Should you?
• This LIC will be shut down if it doesn’t meet target share price

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Sky Network (ASX:SKT) share price plummets 9% on FY20 results appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32f5uhR

The chances of a second stock market crash continue to be elevated. Risks such as an ongoing rise in the number of coronavirus cases, as well as political challenges caused by factors such as the US election and Brexit, may lead to weak investor sentiment in the coming months.

As such, there could be a buying opportunity for long-term investors. Through purchasing high-quality companies at low prices on a regular basis, you could increase your chances of making a million.

Buying high-quality stocks at low prices

Should a second market crash occur, buying the best stocks you can find at the lowest prices could be a sound move. They may not only stand a better chance of surviving a potential economic downturn, but may be better placed to benefit from a likely long-term recovery.

In terms of the quality of a company, this can be assessed through its financial performance. For example, companies with manageable debt levels and a long track record of outperforming their peers in periods of economic difficulty could be more attractive than their rivals. Furthermore, assessing the size of a company’s competitive advantage may help you to find the most attractive businesses. For example, they may have unique products or strong brand loyalty that allows them to deliver rising profitability.

Buying such companies at low prices during a market crash may improve your portfolio’s long-term outlook. While high-quality businesses may not be among the cheapest stocks around, they could be worthy of premium valuations relative to their sector peers.

Buying regularly in a market crash

Should a second market crash occur, buying shares regularly in small amounts may be a logical approach. After all, it is exceptionally difficult to know how long a market decline will last, as well as when its recovery will take place. Therefore, investing a lump sum may mean that you are either too early, or too late, and fail to obtain the most attractive prices.

Many sharedealing providers offer regular investing services. They provide a convenient means of buying stocks on a monthly or weekly basis. In many cases, they charge lower commission versus the standard rate, which may make regular investing no more expensive than investing a lump sum in the stock market.

Making a million

Clearly, it will take time to make a million – even when investing after a market crash. However, the stock market’s high single-digit returns over recent decades show that investing regularly can lead to a surprisingly large nest egg.

For example, investing $750 per month over 30 years could produce a seven-figure portfolio if an 8% annual return is achieved. By investing when shares are cheap, such as after a market decline, you could obtain an even higher rate of return, and improve your chances of making a million.

More reading

• Sky Network (ASX:SKT) share price plummets 9% on FY20 results
• Nearmap (ASX:NEA) share price halted for $90 million capital raising
• Whispir (ASX:WSP) share price sinks 9.5% lower on major shareholder sell-down
• Warren Buffett is investing in this hot tech IPO. Should you?
• This LIC will be shut down if it doesn’t meet target share price

Motley Fool contributor Peter Stephens has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Stock market crash part 2: how I’d capitalise on buying opportunities to make a million appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2GC6Tqb

The Nearmap Ltd (ASX: NEA) share price won’t be taking part in the tech rebound on Thursday after it requested a trading halt.

Why is the Nearmap share price in a trading halt?

This morning Nearmap requested a trading halt whilst it undertakes a capital raising.

According to the release, the company has launched a fully underwritten institutional placement to raise a minimum of $70 million and a non-underwritten share purchase plan aiming to raise a further $20 million.

The pricing of the placement will be determined via an institutional bookbuild with an underwritten floor price of $2.69 per new share. This represents a 6.9% discount to its last close price.

Whereas the share purchase plan will be undertaken at the lower of the placement price and a 2.5% discount to its five-day volume weighted average price at the closing date.

Why is Nearmap raising funds?

Management advised that it is raising the funds to capitalise on the momentum of the business and the tailwinds in the industry.

The proceeds of its capital raising will be deployed across a number of areas of investment. These include scaling its investment in sales and marketing, particularly in North America.

It also intends to expand its product solutions to high-value use cases, which it believes will provide greater engagement and utility to customers.

In addition to this, funds will be used to accelerate the roll out of the HyperCamera3 systems. This will generate expanded coverage at higher fidelity and enable the expansion into new geographical markets.

“Significant opportunity”

CEO and Managing Director, Dr Rob Newman, commented: “Nearmap has continued to scale rapidly over a short period of time and saw particularly strong ACV growth from three core industry verticals in FY20. The Roofing, Insurance and Government verticals have benefited from the increasing attractiveness of our premium content types and we see a significant opportunity for Nearmap to establish a leadership position in each.”

These verticals accounted for 70% of its North American ACV portfolio at the end of FY 2020.

“With our unique technology and subscription business model which no other aerial imagery company has been able to replicate at scale and with the acceleration of investments into strategic growth initiatives, Nearmap continues to focus on the global opportunity to become the world’s leading provider of subscription-based location intelligence.”

Concurrent with the placement, the company non-executive director Ross Norgard is offloading approximately 4.2 million shares. This represents 15.1% of his holding and will leave the director with a relevant interest of 23.6 million shares.

More reading

• Are these the ASX growth shares to buy right now?
• 5 things to watch on the ASX 200 on Thursday
• ASX 200 drops over 2%, tech and oil fall
• How I’d turn $5,000 into $100,000 with ASX growth shares
• Why I would buy Appen and these ASX tech shares after the selloff

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nearmap Ltd. The Motley Fool Australia has recommended Nearmap Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Nearmap (ASX:NEA) share price halted for $90 million capital raising appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2Zou3XB

The Whispir Ltd (ASX: WSP) share price is missing out on the tech rebound on Thursday.

In morning trade the cloud-based communication platform provider’s shares are down 9.5% to $3.85.

As a comparison, the S&P ASX All Technology index is up 2.7%.

Why is the Whispir share price dropping lower?

The Whispir share price has come under pressure after it revealed that some large shareholders have sold down their stakes in the company.

According to the release, 53,000,917 shares were released from escrow on Wednesday. These shares were the final tranche subject to escrow from Whispir’s IPO in June last year.

From these, 20,320,950 shares were sold to new and existing domestic and international investors at a price of $3.81 per share after the market close yesterday. This is a discount of over 10% to its last close price and represents a total consideration of approximately $77.4 million.

Given that Whispir listed on the ASX last week at a price of $1.60, it appears as though these early investors have decided to crystallise some their impressive gains.

According to the AFR, one of those shareholders is believed to be Telstra Corporation Ltd (ASX: TLS). At the last count its Telstra Ventures Fund was the second largest shareholder behind the company’s CEO Jeromy Wells. 

Mr Wells commented: “I would like to thank our formerly escrowed shareholders for their support, before, during and after our IPO in June 2019. Their support has been instrumental in enabling our growth and listing on the ASX.”

“Whispir’s communications workflow platform has a significant global market opportunity, supporting and facilitating long-term macro communications trends in process automation, digital customer engagement and broader digital transformation projects. New customer wins in the second half of FY20 ensure we are well-positioned for growth in FY21 and we remain focused on increasing our international footprint as we welcome new institutional investors to the WSP register,” he concluded.

More reading

• Why I would buy Appen and these ASX tech shares after the selloff
• Why the Telstra share price is a good buy for dividends
• Top ASX growth shares to buy in September 2020
• 3 ASX shares for growth, income, and value investors to buy right now
• ASX 200 Weekly Wrap: Friday crash pulls ASX back below 6,000 points

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Whispir Ltd. The Motley Fool Australia owns shares of and has recommended Telstra Limited. The Motley Fool Australia has recommended Whispir Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Whispir (ASX:WSP) share price sinks 9.5% lower on major shareholder sell-down appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2RcU33G